We published that treatment with an agonistic CD137 antibody prevented T1D in NOD mice, at least partly by targeting and increasing the numbers of the CD4+CD25+CD137+ Treg subset (9). This evidence concerns the gene TNFRSF9 and type 1 diabetes mellitus.